Boardroom Alpha
Boardroom Alpha
RAPP · Additional Proxy Materials (DEFA14A) · Filed April 23, 2026

Rapport Therapeutics Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 23, 2026
Ticker
RAPP
Accession
0001193125-26-171836
Boardroom Alpha · Filing insights

Rapport Therapeutics proposes electing three Class II directors and ratifying PwC for 2026; board recommends voting For both.

About Rapport Therapeutics Inc
Market cap
$1.7B
1Y TSR
+226.9%
Board grade
C
Sector
Healthcare
CEO
Abraham Ceesay
Last annual meeting: Jun 10, 2026 · View full Rapport Therapeutics Inc profile →
DEFA14A
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No. )

 

 

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

 

Preliminary Proxy Statement

 

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

Definitive Proxy Statement

 

Definitive Additional Materials

 

Soliciting Material under §240.14a-12

RAPPORT THERAPEUTICS, INC.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

 

No fee required

 

Fee paid previously with preliminary materials

 

Fee computed on table in exhibit required by Item 25(b) Exchange Act Rules 14a-6(i)(1) and 0-11

 

 
 


 

 

 

LOGO

RAPPORT THERAPEUTICS, INC.

99 HIGH STREET, SUITE 2100

BOSTON, MA 02110

 

 

V89959-P44732

 

 

 

LOGO

 

You invested in RAPPORT THERAPEUTICS, INC. and it’s time to vote!

You have the right to vote on proposals being presented at the 2026 Annual Meeting, which is being held virtually. Important Notice Regarding the Availability of Proxy Materials for the 2026 Annual Meeting of Stockholders to be Held on June 10, 2026.

Get informed before you vote

View the Notice, Proxy Statement and 2025 Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 27, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

 

LOGO

 

Smartphone users       LOGO   

Vote Virtually at the Meeting*

 

Point your camera here and

vote without entering a

control number

      June 10, 2026
      1:00 PM ET
     

LOGO

       Virtually at:
       www.virtualshareholdermeeting.com/RAPP2026
        
          

 

 

*Please check the meeting materials for any special requirements for meeting attendance.


Vote at www.ProxyVote.com

 

 

THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the

upcoming 2026 Annual Meeting. Please follow the instructions

on the reverse side to vote on these important matters.

 

 Voting Items

 

 

Board

Recommends

 

1.

  To elect James Healy, M.D., Ph.D., Robert J. Perez, and Raymond Sanchez, M.D. as Class II Directors.  
 
  Nominees:  
 
   

01)  James Healy, M.D., Ph.D.

02)  Robert J. Perez

03)  Raymond Sanchez, M.D.

  LOGO  For
 

2.

  To ratify the appointment of PricewaterhouseCoopers LLP as Rapport’s independent registered public accounting firm for the fiscal year ending December 31, 2026.  

LOGO  For

NOTE: In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting or any continuations, adjournments and postponements thereof.

   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 

 

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.

V89960-P44732

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Rapport Therapeutics Inc (RAPP)

Reference

Frequently asked questions

When did Rapport Therapeutics Inc file this DEFA14A?
Rapport Therapeutics Inc (RAPP) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 23, 2026. The accession number assigned by EDGAR is 0001193125-26-171836.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Rapport Therapeutics proposes electing three Class II directors and ratifying PwC for 2026; board recommends voting For both. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Rapport Therapeutics Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Rapport Therapeutics Inc has filed under CIK 2012593, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer